Edward R. Conner
CIK 1691265 · Chief Medical Officer · last filed 2025-01-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGMO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
POINT RICHMOND TECH CENTER
RICHMOND, CA 94804
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Third Harmonic Bio, Inc. (THRD) Delisted | Chief Medical Officer | 0 | $5.38 | $0 | -$191.8K | 8 | 2025-01-17 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | — | $14.59 | — | $0 | 3 | 2022-06-03 |
| BOLD | SVP, Chief Medical Officer | 0 | $2.53 | $0 | $0 | 3 | 2020-01-15 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Sr. VP & Chief Medical Officer | 11,291 | $0.18 | $2.0K | -$1.11M | 17 | 2019-01-28 |
Recent Filings · Page 3 of 4
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$52.6K | EDGAR |
| 2018-10-09 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$56.8K | EDGAR |
| 2018-09-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$54.8K | EDGAR |
| 2018-08-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$51.2K | EDGAR |
| 2018-07-09 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$63.0K | EDGAR |
| 2018-06-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$67.4K | EDGAR |
| 2018-05-09 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$65.8K | EDGAR |
| 2018-04-09 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$71.1K | EDGAR |
| 2018-03-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$107.9K | EDGAR |
| 2018-02-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$76.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.